apalutamide + abiraterone acetate + leuprolide acetate

A combination therapy of **apalutamide, abiraterone acetate, and leuprolide acetate** is used as an investigational or experimental regimen for the treatment of very high-risk or advanced prostate cancer. Apalutamide is an androgen receptor inhibitor, abiraterone acetate is a CYP17A1 inhibitor that blocks androgen biosynthesis, and leuprolide acetate is a gonadotropin-releasing hormone (GnRH) agonist that suppresses testicular androgen production. The combination aims to comprehensively suppress androgen signaling through different mechanisms, maximizing testosterone suppression and reducing prostate cancer progression. This multidrug approach is being evaluated primarily for patients with high-risk or metastatic prostate cancer, and is being assessed in the context of combining with advanced radiotherapy regimens.[7]

Other names

Antiandrogen TherapyCombination antiandrogen therapyLeuprolide + Apalutamide + Abiraterone